ASTH 📈 Astrana Health - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03763A2078
ASTH: Care Coordination, Medical Services, Healthcare Management
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California. Web URL: https://www.astranahealth.com
Additional Sources for ASTH Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ASTH Stock Overview
Market Cap in USD | 1,827m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2000-01-13 |
ASTH Stock Ratings
Growth 5y | 45.2% |
Fundamental | 25.8% |
Dividend | - |
Rel. Strength Industry | -230 |
Analysts | 4.82/5 |
Fair Price Momentum | 28.57 USD |
Fair Price DCF | 39.61 USD |
ASTH Dividends
No Dividends PaidASTH Growth Ratios
Growth Correlation 3m | -85.1% |
Growth Correlation 12m | 59.2% |
Growth Correlation 5y | 50.3% |
CAGR 5y | 12.33% |
CAGR/Mean DD 5y | 0.28 |
Sharpe Ratio 12m | -0.12 |
Alpha | -39.78 |
Beta | 1.12 |
Volatility | 53.55% |
Current Volume | 1050.5k |
Average Volume 20d | 315.5k |
What is the price of ASTH stocks?
As of December 22, 2024, the stock is trading at USD 33.70 with a total of 1,050,500 shares traded.
Over the past week, the price has changed by -10.44%, over one month by -17.88%, over three months by -40.88% and over the past year by -6.70%.
As of December 22, 2024, the stock is trading at USD 33.70 with a total of 1,050,500 shares traded.
Over the past week, the price has changed by -10.44%, over one month by -17.88%, over three months by -40.88% and over the past year by -6.70%.
Is Astrana Health a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Astrana Health is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.84 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ASTH as of December 2024 is 28.57. This means that ASTH is currently overvalued and has a potential downside of -15.22%.
Neither. Based on ValueRay Fundamental Analyses, Astrana Health is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.84 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ASTH as of December 2024 is 28.57. This means that ASTH is currently overvalued and has a potential downside of -15.22%.
Is ASTH a buy, sell or hold?
Astrana Health has received a consensus analysts rating of 4.82. Therefor, it is recommend to buy ASTH.
Astrana Health has received a consensus analysts rating of 4.82. Therefor, it is recommend to buy ASTH.
- Strong Buy: 10
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for ASTH stock price target?
According to ValueRays Forecast Model, ASTH Astrana Health will be worth about 31.5 in December 2025. The stock is currently trading at 33.70. This means that the stock has a potential downside of -6.56%.
According to ValueRays Forecast Model, ASTH Astrana Health will be worth about 31.5 in December 2025. The stock is currently trading at 33.70. This means that the stock has a potential downside of -6.56%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 67.1 | 99.1% |
Analysts Target Price | 49.7 | 47.4% |
ValueRay Target Price | 31.5 | -6.6% |